Long-term efficacy and safety of polyacrylamide hydrogel injection in the treatment of human immunodeficiency virus-related facial lipoatrophy: A 5-year follow-up

Plastic and Reconstructive Surgery

Volumn 129, Issue 1, 2012, Pages 101-109

  De Santis, Giorgio ^a   Pignatti, Marco ^a   Baccarani, Alessio ^a   Pedone, Antonio ^a   Spaggiari, Antonio ^a   Orlando, Gabriella ^a   Guaraldi, Giovanni ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLIC ACID RESIN; AQUAMID;

ADULT; ARTICLE; FACE; FEMALE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HYDROGEL; INJECTION; MALE; MIDDLE AGED; PROSTHESES AND ORTHOSES; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ACRYLIC RESINS; ADULT; FACE; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYDROGELS; INJECTIONS; MALE; MIDDLE AGED; PROSTHESES AND IMPLANTS; TREATMENT OUTCOME;

EID: 84555217970     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e3182362142     Document Type: Article

References (30)

1. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350:1220-1234.
2. Echavez M, Horstman W. Relationship between lipoatrophy and quality of life. AIDS Read. 2005;15:369-375.
3. Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read. 2000; 10:546-550.
4. Guaraldi G, Luzi K, Murri R, et al. Sexual dysfunction in HIV-infected men: Role of antiretroviral therapy, hypogonadism and lipodystrophy. Antivir Ther. 2007;12:1059-1065.
5. Nguyen A, Calmy A, Schiffer V, et al. Lipodystrophy and weight changes: Data from the Swiss HIV Cohort Study, 2000-2006. HIV Med. 2008;9:142-150.
6. Benn P, Sauret-Jackson V, Cartledge J, et al. Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors. HIV Med. 2009;10:351-355.
7. Hammond E, McKinnon E, Nolan D. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: Prevalence and metabolic consequences. Clin Infect Dis. 2010;51:591-599.
8. Jones D. HIV facial lipoatrophy: Causes and treatment options. Dermatol Surg. 2005;31:1519-1529; discussion 1529.
9. Christensen LH, Breiting VB, Aasted A, Jørgensen A, Kebuladze I. Long term effects of polyacrylamide hydrogel on human breast tissue. Plast Reconstr Surg. 2003;111:1883-1890.
10. de Cássia Novaes W, Berg A. Experience with a new non biodegradable hydrogel (Aquamid): A pilot study. Aesthetic Plast Surg. 2003;27:376-380.
11. Christensen L, Breiting V. Complications induced by polyacrylamide hydrogel injection. Plast Reconstr Surg. 2005;116: 1168-1169.
12. Pallua N, Wolter TP. A 5-year assessment of safety and aesthetic results after facial soft-tissue augmentation with polyacrylamide hydrogel (Aquamid): A prospective multicenter study of 251 patients. Plast Reconstr Surg. 2010;125:1797-1804.
13. Amin SP, Marmur ES, Goldberg DJ. Complications from injectable polyacrylamide gel, a new nonbiodegradable soft tissue filler. Dermatol Surg. 2004;30:1507-1509.
14. Guaraldi G, Orlando G, De Fazio D, et al. Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: A prospective study. Antivir Ther. 2005;10:753-759.
15. De Santis G, Jacob V, Baccarani A, et al. Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: A 2-year clinical experience. Plast Reconstr Surg. 2008;121:644-653.
16. Fontdevila JBJ, Prades E, Pujol T, et al. Validation of a simple classification for facial lipoatrophy in HIV-infected adults. Antivir Ther. 2007;12(Suppl 2):L31.
17. Bello G, Jackson IT, Keskin M, et al. The use of polyacrylamide gel in soft-tissue augmentation: An experimental assessment. Plast Reconstr Surg. 2007;119:1326-1336.
18. Silvers SL, Eviatar JA, Echavez MI, Pappas AL. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: One-year durability. Plast Reconstr Surg. 2006;118(3 Suppl):34S-45S.
19. Guaraldi G, Orlando G, Murri R, et al. Quality of life and body image in the assessment of psychological impact of lipodystrophy: Validation of the Italian version of assessment of body change and distress questionnaire. Q Life Res. 2006; 15:173-178.
20. Grunfeld C, Saag M, Cofrancesco J Jr, et al. Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy. AIDS 2010;24:1717-1726.
21. HodderSL.Thegraying of an epidemic: Clinical considerations of HIV and aging. Available at: http://healthmatterscme.com/PdfPlayerPage.aspx?id-165. Accessed December 1, 2010.
22. Bechara FG, Gambichler T, Brockmeyer NH, Sand M, Altmeyer P, Hoffmann K. Hyaluronic acid new formulation: Experience in HIV-associated facial lipoatrophy. Dermatology 2008;217:244-249.
23. Moyle GJ, Lysakova L, Brown S, et al. A randomized open label study of immediate vs. delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med. 2004;5:82-97.
24. Guaraldi G, Fontdevila J, Christensen LH, et al. Surgical correction of HIV-associated facial lipoatrophy. AIDS 2011; 25:1-12.
25. Valantin MA, Aubron-Olivier C, Ghosn J, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: Results of the open-label study VEGA. AIDS 2003;17:2471-2477.
26. Skeie L, Bugge H, Negaard A, Bergersen BM. Large particle hyaluronic acid for the treatment of facial lipoatrophy in HIV-positive patients: 3-year follow-up study. HIV Med. 2010; 11:170-177.
27. Negredo E, Puig J, Aldea D, et al. Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy. AIDS Res Hum Retroviruses 2009;25:451-455.
28. Negredo E, Higueras C, Adell X, et al. Reconstructive treatment for antiretroviral-associated facial lipoatrophy: A prospective study comparing autologous fat and synthetic substances. AIDS Patient Care STDS. 2006;20:829-837.
29. Bugge H, Negaard A, Skeie L, Bergersen B. Hyaluronic acid treatment of facial fat atrophy in HIV-positive patients. HIV Med. 2007;8:475-482.
30. Christensen L. Normal and pathologic tissue reactions to soft tissue gel fillers. Dermatol Surg. 2007;33(Suppl 2):S168-S175.